Onconetix unit Proteomedix launches Proclarix U.S. validation study with Labcorp
PUBT · 5d ago
Share
Listen to the news
- Onconetix reported Q1 2026 progress at wholly owned Swiss subsidiary Proteomedix, highlighting two peer-reviewed studies supporting Proclarix use to cut unnecessary prostate biopsies.
- Proteomedix initiated PRIME, a US multi-center validation study with Labcorp, enrolling first participants with target up to 500 men across multiple ethnicities.
- European rollout advanced, with Proclarix offered in a UK real-world screening initiative that ran close to 100 tests during Q1, alongside steps toward expansion into Turkey.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130925PRIMZONEFULLFEED9719427) on May 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved